Skip to main content
logo
NewAmsterdam Pharma Company N.V. (NAMS)
NASDAQ: NAMS · Real-Time Price · USD
23.32
+0.74 (3.28%)
At close: Sep 22, 2026, 4:00 PM EDT
23.70
+0.38 (1.63%)
Pre-market: Sep 23, 2026, 8:14 AM EDT

NAMS Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
7.1222.545.5614.09102.69-
Revenue Growth
-88.87%-50.61%223.37%-86.28%--
Gross Profit
7.1222.545.5614.09102.69-
Operating Income
-244.41-225.68-176.29-182.97-3.56-34.98
Net Income
-259.5-203.82-241.6-176.94-22.63-41.79
Earnings Per Share
-2.14-1.72-2.56-2.15-1.19-3.81
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
678.26728.85834.19340.45467.7360.38
Total Debt
0.080.20.450.060.130.19
Net Cash (Debt)
678.18728.65833.74340.39467.660.19
Net Cash Growth
-13.39%-12.61%144.94%-27.21%676.83%-
Net Cash Per Share
5.606.158.844.1424.655.48

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-143.46-147.78-158.56-141.2210.67-29.51
Capital Expenditures
-0.26-0.25-0.67-0.02-0.22-0.02
Free Cash Flow
-143.72-148.03-159.24-141.2410.44-29.54
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%-
Operating Margin
-3432.20%-1002.90%-386.91%-1298.56%-3.46%-
Pretax Margin
-3644.21%-905.74%-530.25%-1255.57%-22.04%-
Profit Margin
-3644.21%-905.74%-530.25%-1255.76%-22.04%-
FCF Margin
-2018.28%-657.82%-349.49%-1002.43%10.17%-

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
P/FCF Ratio
----85.12-
PS Ratio
391.46176.7760.3865.268.66-